REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Only 10 to 15% of tumours are suitable for surgical resection. As of 2018, when chemotherapy is given the FOLFIRINOX regimen containing fluorouracil, irinotecan, oxaliplatin and leucovorin has been shown to extend survival beyond traditional gemcitabine regimens. For the most part, treatment is palliative, focusing on the management of symptoms that develop. This may include management of itch, a choledochojejunostomy, or the insertion of stents with ERCP to facilitate the drainage of bile, and medications to help control pain. In the United States, pancreatic cancer is the fourth most common cause of death due to cancer. The disease occurs more often in the developed world, which had 68% of new cases in 2012. Pancreatic adenocarcinoma typically has poor outcomes, with the average percentage alive for at least one and five years after diagnosis being 25% and 5% respectively. In localized disease where the cancer is small (< 2 cm) the number alive at five years is approximately 20%. There are several types of pancreatic cancer, involving both the endocrine and exocrine tissue. The many types of pancreatic endocrine tumors are all uncommon or rare, and have varied outlooks. However, the incidence of these cancers has been rising sharply; it is not clear to what extent this reflects increased detection, especially through medical imaging, of tumors that would be very slow to develop. Insulinomas (largely benign) and gastrinomas are the most common types.
Physical presence may be required for women who are in relationships for the testosterone–partner interaction, where same-city partnered women have lower testosterone levels than long-distance partnered women.
== Technologies == Camurus is a company focused on the development of lipid lyotropic liquid crystal structures for pharmaceutical drug delivery applications. These structures are well-defined three-dimensional formations consisting of lipophilic and hydrophilic domains that can be either interconnected or isolated depending on the environmentally induced phase conditions. The unique crystalline structures offer a unique way of encapsulating and transporting Active pharmaceutical ingredients, such as small molecules, peptides and proteins through the body. The structures also allow for the use of controlled release and prevention of degradation of fragile short half live molecules, a serious issue for amino-acid based drugs.
In a Kendrick mass analysis, the Kendrick mass defect is plotted as function of nominal Kendrick mass for ions observed in a mass spectrum. Ions of the same family, for example the members of an alkylation series, have the same Kendrick mass defect but different nominal Kendrick mass and are positioned along a horizontal line on the plot. If the composition of one ion in the family can be determined, the composition of the other ions can be inferred. Horizontal lines of different Kendrick mass defect correspond to ions of different composition, for example degree of saturation or heteroatom content. A Kendrick mass analysis is often used in conjunction with a Van Krevelen diagram, a two- or three- dimensional graphical analysis in which the elemental composition of the compounds are plotted according to the atomic ratios H/C, O/C, or N/C.
Sources: en.wikipedia.org
==== Needle exchange programs ==== The CDC defines needle exchange programs (NEP), also known as syringe services programs, as "community-based programs that provide access to sterile needles and syringes free of cost and facilitate safe disposal of used needles and syringes". NEP were first established in the US in the late 1980s as a response to the HIV pandemic. Because federal funding has long been banned from being used for NEP, their prominence in the US has been minimal. However, in early 2016, in the face of the ever-increasing heroin crisis, Congress effectively rolled back those regulations and is now allowing federal funding to support certain aspects of NEP. NEP are cited by the CDC as a vital aspect of the multi-faceted approach to the opioid crisis. While opposition to NEP includes fears of increased drug use, studies have shown that they do not increase drug use among users or within a community. NEP have also been known to increase admittance into addiction treatment centers, offer counseling, housing support and help users begin the path to recovery through outreach from trusted staff. In addition, NEP that operate on a one-for-one basis help to drastically reduce the amount of discarded needles in public. Both the Centers for Disease Control and National Institute of Health support the idea that NEP are a crucial aspect to a comprehensive approach to the opioid crisis.
==== Prodromal phase ==== MS may have a prodromal phase in the years leading up to its manifestation, characterized by psychiatric issues, cognitive impairment, and increased use of healthcare. People later diagnosed with MS may seek healthcare for fatigue, bladder issues, headaches and other pain disorders.
== Quadrupole time-of-flight == Quadrupole time-of-flight mass spectrometry (QToF-MS) has a similar configuration to a tandem mass spectrometer with a mass-resolving quadrupole and collision cell hexapole, but instead of a second mass-resolving quadrupole, a time-of-flight mass analyzer is used. Both quadrupoles can operate in RF mode only to allow all ions to pass through to the mass analyzer with minimal fragmentation. To increase spectral detail, the system takes advantage of collision-induced dissociation. Once the ions reach the flight tube, the ion pulser sends them upwards towards the reflectron and back down into the detector. Since the ion pulser transfers the same kinetic energy to all molecules, the flight time is dictated by the mass of the analyte. QToF is capable of measuring mass to the 4th decimal place and is frequently used for pharmaceutical and toxicological analysis as a screening method for drug analogues. Identification is done by collection of the mass spectrum and comparison to tandem mass spectrum libraries.
Sources: en.wikipedia.org
Ultraviolet radiation is helpful in the treatment of skin conditions such as psoriasis and vitiligo. Exposure to UVA, while the skin is hyper-photosensitive, by taking psoralens is an effective treatment for psoriasis. Due to the potential of psoralens to cause damage to the liver, PUVA therapy may be used only a limited number of times over a patient's lifetime. UVB phototherapy does not require additional medications or topical preparations for the therapeutic benefit; only the exposure is needed. However, phototherapy can be effective when used in conjunction with certain topical treatments such as anthralin, coal tar, and vitamin A and D derivatives, or systemic treatments such as methotrexate and Soriatane.
Following the release of his mixtape Hologram Panda with producer Dame Grease, Riff Raff told MTV that his upcoming Mad Decent second studio album would be titled Riff Raff, The Neon Icon, later shortened to Neon Icon. In February 2013 he told Complex that his second studio album is due out some time during the third quarter of 2013. On June 25, 2013, he released a single titled "Dolce & Gabbana", produced by DJ Carnage as the first single from Neon Icon, however two days later he announced that the song wouldn't be included on the album. He was also featured on Far East Movement's single "The Illest" around the same time. Then on July 12, 2013, he released another non album single titled "Mr. Popular", and four days later released the music video for the song. In August 2013, Riff Raff announced that he would be releasing a collaboration album with Action Bronson titled Galaxy Gladiators in 2014. On November 26, 2013, he released the first official single for Neon Icon titled "How To Be the Man" and produced by DJ Mustard. That same month, Riff Raff told Rolling Stone in an interview that leading up to the album's release he would release various "left-over" tracks from the album's recording sessions These notably included the Boi-1da produced "Real Boyz", featuring rappers OJ da Juiceman and Cap 1, as well as "Suckas Askin' Questions" with Lil Debbie and "Shoulda Won a Grammy" with Action Bronson. In March 2014, prior to the album's release, Rolling Stone included the album on their list of "27 Must-Hear Albums of 2014".
== Geology == Motion between the Kula Plate and the North American Plate along the margin of the Bering Shelf (in the Bering Sea north of the Aleutian arc) ended in the early Eocene. The Aleutian Basin, the ocean floor north of the Aleutian arc, is the remainder of the Kula Plate that was trapped when volcanism and subduction jumped south to its current location at c. 56 Ma. The Aleutian island arc formed in the Early Eocene (55–50 Ma) when the subduction of the Pacific Plate under the North American Plate began. The arc is made of separate blocks that have been rotated clockwise. The basement underlying the islands is made of three stratigraphic units: an Eocene layer of volcanic rock, an Oligocene–Miocene layer of marine sedimentary rock, and a Pliocene–Quaternary layer of sedimentary and igneous rock.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.